Teweida 特维达 Emtricitabine/Tenofovir 200mg/300mg | Qilu Generic | GLT

Generic Information: Teweida 特维达 (China)

Teweida (特维达) is Qilu Pharmaceutical's generic fixed-dose combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, approved by the National Medical Products Administration under 国药准字H20213275. Supplied as thirty film-coated tablets per box, it is among the first wave of Chinese generics of the originator Truvada, bringing the essential two-drug HIV backbone within reach of domestic patients and overseas buyers alike.

What Is 特维达 (Teweida) Used For?

特维达 is used to treat and to help prevent HIV-1. In treatment it is combined with other antiretroviral medicines to control HIV-1 in adults and adolescents of at least 35 kg; in prevention it is taken as pre-exposure prophylaxis to reduce the chance of sexually acquired HIV-1 in people who test negative. Qilu's early domestic approval made it one of the accessible options in China's HIV supply.

How Does 特维达 Work?

The two ingredients are reverse transcriptase inhibitors that block HIV from copying its genetic material. Emtricitabine, a cytidine analogue, and tenofovir, an adenosine analogue, are activated inside cells into metabolites that the viral enzyme mistakes for normal nucleosides; their incorporation severs the growing DNA chain, halting replication. Together they form a two-pronged barrier against a single, essential target.

Indications

特维达 is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients of at least 35 kg, and for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in at-risk, HIV-negative adults and adolescents of at least 35 kg. It is not a hepatitis B therapy, and stopping it in HBV co-infection can provoke a flare, so liver status is checked before use.

Dosage

One tablet is taken once daily, with or without food, supplying 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate. Renal function is assessed before and during therapy, and the interval is lengthened in moderate impairment. For PrEP, a negative HIV test is documented before starting and repeated regularly during use.

Side Effects

Nausea, diarrhea, headache and fatigue are the most frequent early effects and usually settle as treatment continues. The main long-term concerns are kidney impairment and decreased bone mineral density, largely from tenofovir disoproxil, so renal monitoring is routine. Rare serious warnings include lactic acidosis with liver enlargement and hepatitis B flare after discontinuation.

Storage

特维达 tablets are kept at room temperature in their original packaging, away from moisture and heat, with no cold storage required. Ambient shipping keeps logistics simple, and GLT dispatches from a Hong Kong-licensed facility with batch documentation and a certificate of analysis.

Why Choose 特维达 Through GLT?

Qilu is a major Chinese pharmaceutical manufacturer, and its early-approved generic delivers the emtricitabine/tenofovir backbone at a domestic price point that suits long-term therapy. GLT's Hong Kong base and China-focused supply chain make this product readily available to overseas buyers with documented, traceable sourcing.

How to Order

To order 特维达 (Teweida, emtricitabine/tenofovir disoproxil fumarate) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, pack options and delivery timelines to your country, and dispatch from a Hong Kong-licensed facility.

FAQ

Is 特维达 a generic of Truvada? Yes — it contains emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, approved under 国药准字H20213275.

Who manufactures it? Qilu Pharmaceutical, a leading Chinese producer, holds the approval for this generic combination.

Can it be taken for PrEP? Yes — in HIV-negative people it lowers the risk of sexually acquired HIV-1, with the required testing safeguards.